Short Summary
Aardevo North America challenges Agventure's 2021 potato hybrid seed patent, asserting that all ten claims are anticipated or obvious based on decades of prior art. The petition lists nine grounds covering anticipation and obviousness over publications dating back to 1971. No secondary considerations are offered.
Detailed Summary
In a petition for inter partes review of U.S. Patent No. 11,140,841 B2, Aardevo North America, LLC (joined by Aardevo B.V., the JR Simplot Company, and KWS SAAT SE & Co. KGaA) seeks institution of an IPR against Agventure B.V.'s hybrid seed potato breeding patent. The petitioner contends that claims 1‑10 are unpatentable because they are either anticipated (Jong, US‑W4, RH89‑039‑16) or obvious (combinations of Jong, Chase, Bamberg, Phumichai, Spooner, Springer, US‑W4, RH89‑039‑16). Detailed grounds cite specific prior‑art references, demonstrate that the Sli gene and diploid inbreeding methods were known before the 2009 priority date, and argue that the examiner erred in rejecting these references. No secondary considerations of non‑obviousness are presented, and the petition requests that the Board institute the IPR.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Aardevo North America, LLC et al. vs Agventure B.V. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Avanos Medical, Inc.vsStratus Medical, LLC
Avanos Medical filed a Petition challenging Stratus Medical's RF neurotomy needle patent ('782 Patent). The central argument is that the claimed device is obvious because it merely combines conventional features from prior art references like Racz, Fitz, and Lee. This challenges 27 claims related to advanced medical ablation technology.
Samsung Electronics Co., Ltd. et al.vsOne-E-Way, Inc.
The USPTO granted institution for IPR2025-01540 after reviewing the merits. The petitioner successfully demonstrated a reasonable likelihood of prevailing on at least one challenged claim.
Koki Holdings America Ltd. et al.vsKyocera Senco Industrial Tools, Inc.
Koki Holdings and Kyocera Senco reached a settlement over U.S. Patent 11,034,007 and jointly moved to terminate IPR2025-00261, requesting the settlement be kept confidential under 35 U.S.C. §317(b) and 37 C.F.R. §42.74(c).
Atossa Therapeutics, Inc.vsJina Pharmaceuticals, Inc.
Atossa Therapeutics and Jina Pharmaceuticals have settled their dispute over U.S. Patent 12,245,997 and filed a joint motion to terminate the post‑grant review. The motion relies on 35 U.S.C. § 327(a) and cites Board precedent for terminating settled proceedings.
Samsung Electronics Co., Ltd. et al.vsMassively Broadband LLC
Samsung Electronics files an IPR petition challenging Massively Broadband’s ’700 Patent, asserting that its claims are obvious over prior‑art references Daley, Aaron and Scherzer. The petition seeks institution of the review.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.